Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 24
  1. May 05, 2026 · 09:31 · MBIO · Routine +

    Patents Filed

    MindBio Develops Cross-Language AI Speech Analytics Capability for Intoxication Detection Patent applications filed in 15 world firsts using Voice and AI

    01
  2. May 05, 2026 · 07:31 · BPC · Routine +

    BPC Secures C$1.3M Warrant Proceeds Amidst Marketing Spend Surge

    C$1.3 Million in Proceeds Received by The Precision Peptide Company from Warrant Exercises

    02
  3. May 05, 2026 · 07:17 · SONA · Routine +

    Sona Nanotech Maps Melanoma Path After Feasibility Win

    Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

    03
  4. May 05, 2026 · 07:06 · ROVA · Routine +

    Altrova Health Unveils O-Spray Amid Strategic Pivot, Yet Execution Risks Loom

    Altrova Health Announces Launch of O-Spray Product Line and Provides Corporate Update

    04
  5. May 05, 2026 · 07:00 · EPRX · Routine +

    Eupraxia Confirms Dose-Response in EoE Trial; Phase 2b Data Due Q4

    Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

    05
  6. May 05, 2026 · 06:31 · THRM · Routine +

    Therma Bright Secures Repeat Orders, But Scale Remains Questionable Amidst Capital Needs

    Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets

    06
  7. May 04, 2026 · 17:23 · TLT · Routine +

    Theralase Confirms Bladder Cancer Submission Timeline Amidst Continued Burn Rate

    Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

    07
  8. May 04, 2026 · 08:00 · AIDR · Routine −

    Revenue Growth Validates Model But Unsustainable Burn Rate Signals Near-Term Dilution Risk

    Rocket Doctor AI Reports Strong 2025 Results, Validating Physician-Led Model with Key U.S. Payer Contracts and AI Innovation

    08
  9. May 01, 2026 · 19:44 · VVTM · Material −

    VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

    VVT Med Announces Receipt of Management Cease Trade Order

    09
  10. May 01, 2026 · 18:00 · ONCO · Routine +

    Onco-Innovations Advances Manufacturing Scale-Up Amidst 98% Stock Decline and Dilution Concerns

    Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

    10
  11. May 01, 2026 · 17:00 · PCRX · Routine +

    PharmaCorp Rx Inc.

    PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

    11
  12. May 01, 2026 · 14:40 · ADPT · Routine +

    Adaptogenics Health Corp.

    Adaptogenics Health Corp. Announces Strategic Review of Health & Wellness Opportunities and Management Changes

    12
  13. May 01, 2026 · 09:26 · PAIN · Routine +

    Vector Science Files Patent for Pancreatic Cancer Platform Following TSXV Listing

    Vector Science & Therapeutics Files Provisional Patent for Novel Microneedle Catheter Platform for Intratumoral Drug Delivery

    13
  14. May 01, 2026 · 08:01 · BIOV · Routine +

    BioVaxys Preclinical Validation Amidst Compliance Overhang and Liquidity Constraints

    BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

    14
← Newer Older →